189 related articles for article (PubMed ID: 30222203)
1. Acquisition of resistance to vemurafenib leads to interleukin-10 production through an aberrant activation of Akt in a melanoma cell line.
Inozume T; Tsunoda T; Morisaki T; Harada K; Shirasawa S; Kawamura T
J Dermatol; 2018 Dec; 45(12):1434-1439. PubMed ID: 30222203
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
[TBL] [Abstract][Full Text] [Related]
3. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
[TBL] [Abstract][Full Text] [Related]
4.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
5. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
7. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.
Díaz-Martínez M; Benito-Jardón L; Alonso L; Koetz-Ploch L; Hernando E; Teixidó J
Cancer Res; 2018 Feb; 78(4):1017-1030. PubMed ID: 29229605
[TBL] [Abstract][Full Text] [Related]
8. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
9. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
12. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
[TBL] [Abstract][Full Text] [Related]
13. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
14. The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
Zhao B; Cheng X; Zhou X
Melanoma Res; 2018 Dec; 28(6):521-526. PubMed ID: 30192303
[TBL] [Abstract][Full Text] [Related]
15. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
16. Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.
Mologni L; Costanza M; Sharma GG; Viltadi M; Massimino L; Citterio S; Purgante S; Raman H; Pirola A; Zucchetti M; Piazza R; Gambacorti-Passerini C
Neoplasia; 2018 May; 20(5):467-477. PubMed ID: 29605720
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.
Dratkiewicz E; Simiczyjew A; Pietraszek-Gremplewicz K; Mazurkiewicz J; Nowak D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877948
[TBL] [Abstract][Full Text] [Related]
18. [Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
Ryabaya OO; Malysheva AA; Khochenkova YA; Solomko ES; Khochenkov DA
Mol Biol (Mosk); 2018; 52(3):466-473. PubMed ID: 29989578
[TBL] [Abstract][Full Text] [Related]
19. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
[TBL] [Abstract][Full Text] [Related]
20. The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations.
Choi SH; Shin I; Kim N; Nam Y; Sim T
Biochem Biophys Res Commun; 2020 Nov; 532(2):315-320. PubMed ID: 32873393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
